Vanda Pharmaceuticals reports Phase III results showing NEREUS reduces GLP-1 therapy-associated vomiting by 27%

Vanda Pharmaceuticals announced positive Phase III results from Study 3601 showing NEREUS (tradipitant) met its primary endpoint, a 27% relative reduction in any vomiting episodes associated with GLP-1 receptor agonist therapy compared to placebo (p=0.006).

Detected & updated continuously · Source: Nebula